← Eichor
Study identifier: NCT04403867 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

The Role of Micrometastasis and Isolated Tumor Cells (ITCs) in Endometrial and Cervical Cancer. A Multicenter Study.

Condition: Endometrial Cancer · Cervical Cancer · Sentinel Lymph Node  ·  Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

PhaseN/A
Planned participants500
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

The role of small-volume lymph node disease (ITC and micro metastases) among patients with endometrial or cervical cancer submitted to sentinel node (SLN) procedure is not clearly defined. This study was designed to create a dataset of patients with lymph nodal disease. Data on type and volume of lymph nodal disease, therapeutic choices and oncological outcomes (DFS, OS, recurrence rate) will be collected and analyzed. This will allow to define the groups of patients who may need or for whom it can be avoided any adjuvant treatment on the basis of lymph node status.

This description comes directly from the study's public registry record.

Talk to the study team

Fabio Martinelli, MD  ·  +390223903322  ·  fabio.martinelli@istitutotumori.mi.it

Always discuss trial participation with your own doctor first.

Locations (1)

Fondazione IRCCS Istituto Nazionale dei TumoriMilan, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04403867